Biotech companies in the United States by short interest
Shares sold short and not yet covered, as reported to FINRA for the latest settlement date, as a percent of shares outstanding (market value divided by share price), not of the smaller float.
Scholar Rock Holding leads the 20 biotech companies in the United States ranked by short interest, at 19.2%, ahead of Twist Bioscience (14.4%) and Kodiak Sciences (12.4%). Figures as of the 30 Oct 2026 settlement date, from FINRA's short interest report, with shares outstanding from Yahoo Finance quotes.
Key facts
- Companies ranked
- 20
- First
- Scholar Rock Holding19.2%
- Median
- 9.77%
- Combined market value
- AED 2.7T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | Short interest % ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock HoldingSRRK · Health Care | 19.2% | AED 22.6B | AED 185.01 | 4.94% up | 26% up | ||
| 2 | Twist BioscienceTWST · Health Care | 14.4% | AED 28B | AED 409.98 | 4.07% down | 346% up | ||
| 3 | Kodiak SciencesKOD · Health Care | 12.4% | AED 23.5B | AED 359.59 | 0.09% up | 399% up | ||
| 4 | Halozyme TherapeuticsHALO · Health Care | 12.0% | AED 39B | AED 341.74 | 2.88% down | 39% up | ||
| 5 | ImmunityBioIBRX · Health Care | 11.9% | AED 25.7B | AED 24.13 | 1.94% down | 232% up | ||
| 6 | RepligenRGEN · Health Care | 11.0% | AED 40B | AED 625.48 | 1.38% down | 12% up | ||
| 7 | ExelixisEXEL · Health Care | 10.5% | AED 59B | AED 241.79 | 3.60% down | 63% up | ||
| 8 | CG OncologyCGON · Health Care | 10.3% | AED 26.9B | AED 300.82 | 2.38% up | 97% up | ||
| 9 | Krystal BiotechKRYS · Health Care | 10.3% | AED 34.4B | AED 1,160.01 | 0.15% up | 54% up | ||
| 10 | Kymera TherapeuticsKYMR · Health Care | 9.84% | AED 37.4B | AED 438.52 | 1.44% down | 87% up | ||
| 11 | VaxcytePCVX · Health Care | 9.70% | AED 33.9B | AED 214.36 | 0.27% down | 23% up | ||
| 12 | ImmunovantIMVT · Health Care | 8.96% | AED 24.7B | AED 119.45 | 1.96% down | 46% up | ||
| 13 | ModernaMRNA · Health Care | 8.20% | AED 296.2B | AED 732.14 | 1.29% up | 780% up | ||
| 14 | Adaptive BiotechnologiesADPT · Health Care | 7.09% | AED 16.7B | AED 103.03 | 1.44% down | 74% up | ||
| 15 | Revolution MedicinesRVMD · Health Care | 6.05% | AED 126.7B | AED 585.59 | 0.24% down | 129% up | ||
| 16 | Neurocrine BiosciencesNBIX · Health Care | 5.83% | AED 58.2B | AED 575.16 | 3.85% down | 17% up | ||
| 17 | Bio-TechneTECH · Health Care | 4.90% | AED 41.9B | AED 267.03 | 0.07% down | 24% up | ||
| 18 | BiogenBIIB · Health Care | 3.69% | AED 134.2B | AED 907.71 | 1.70% down | 49% up | ||
| 19 | AmgenAMGN · Health Care | 2.33% | AED 871.8B | AED 1,611.79 | 1.14% down | 32% up | ||
| 20 | Gilead SciencesGILD · Health Care | 1.72% | AED 758.7B | AED 611.66 | 1.45% down | 35% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; short interest from FINRA, the owner and source of the data, as of the 30 Oct 2026 settlement date.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Source: FINRA. Short interest is the shares sold short and not yet covered as brokers reported them to FINRA for the 30 Oct 2026 settlement date; FINRA publishes it about seven business days later, so it is not today's figure. It is divided by shares outstanding worked out as the market value over the share price, both from the same quote — not by the float, so the percent reads lower than a percent of float would. For a company with more than one class of shares the market value covers every class, which lowers it further. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6730 AED).
Questions and answers
Which biotech companies in the United States rank first by short interest?
Scholar Rock Holding (19.2%), Twist Bioscience (14.4%) and Kodiak Sciences (12.4%) are the top three of the 20 biotech companies in the United States ranked by short interest as of the 30 Oct 2026 settlement date.
How many biotech companies in the United States are in this ranking?
20 are ranked by short interest.
What are these biotech companies in the United States worth together?
The 20 biotech companies in the United States ranked by short interest have a combined market value of AED 2.7T as of the 30 Oct 2026 settlement date.
What does ranking by short interest measure?
Shares sold short and not yet covered, as reported to FINRA for the latest settlement date, as a percent of shares outstanding (market value divided by share price), not of the smaller float.
Learn how this ranking works
All markets guides →- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
Cite this page
Funkfolio, “Biotech companies in the United States by short interest”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=short-interest
Underlying data: FINRA short interest (the 30 Oct 2026 settlement date); Yahoo Finance.